Indian leading generic drug manufacturer, Natco pharma submits the generic version of ibrutinib drug approval application to USFDA.
The strength would be 140 mg, 280 mg, 420 mg and 560 mg.
This medicine is used for treating certain types of cancer.
This medicine would be generic equivalents to Imbruvica tablet.
The Imbruvica is an international brand which is owned by Janssen Biotech Inc.
At present, the only generic version of ibrutinib is available which manufacturing Bangladesh pharma company Beacon Pharmaceuticals Limited with the name of Ibrutix